SEARCH

SEARCH BY CITATION

References

  • Anderson, G.D., Hauser, S.D., McGarity, K.L., Bremer., M.E., Isakson, P.C. & Gregory, S.A. (1996) Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. Journal of Clinical Investigation, 97, 26722679.
  • Appleton, I., Tomlinson, A., Mitchell, J.A. & Willoughby, D.A. (1995) Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation. Implications for future anti-inflammatory therapy. Journal of Pathology, 176, 413420.
  • Baraf, H.S.B., Fuentealba, C., Greenwald, M., Brzezicki, J., O’Brien, K., Soffer, B., Polis, A., Bird, S., Kaur, A. & Curtis, S.P., for the EDGE Study Group (2007) Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the etoricoxib versus diclofenac sodium gastrointestinal tolerability and effectiveness (EDGE) trial. Journal of Rheumatology, 34, 408420.
  • Bettini, R., Grossi, E., Rapazzini, P. & Giardina, G. (1986) Diclofenac sodium versus acetylsalicylic acid: a randomized study in febrile patients. Journal of Internal Medicine Research, 14, 95100.
  • Blobaum, A.L. & Marnett, L.J. (2007) Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib. Journal of Biology Chemistry, 282, 1637916390.
  • Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M.B., Hawkey, C.J., Hochberg, M.C., Kvien, T.K. & Schnitzer, T.J. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343, 15201528.
  • Brune, K. & Furst, D.E. (2007) Combining enzyme selectivity and tissue selectivity of cyclooxygenase inhibitors: towards better tolerability. Rheumatology, 46, 911919.
  • Brune, K. & Hinz, B. (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scandinavian Journal of Rheumatology, 33, 16.
  • Callan, O.H., So, O.Y. & Swinney, D.C. (1996) The kinetic factors that determine the affinity and selectivity for slow binding inhibition of human prostaglandin H synthase 1 and 2 by indomethacin and flurbiprofen. Journal of Biological Chemistry, 271, 35483554.
  • Capone, M.L., Tacconelli, S., Francesco, L.D., Sacchetti, A., Sciulli, M.G. & Patrignani, P. (2007) Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins & other Lipid Mediators, 82, 8594.
  • Chan, C.C., Boyce, S., Brideau, C., Charleson, S., Cromlish, W., Ethier, D., Evans, J., Ford-Hutchinson, A.W., Forrest, M.J., Gauthier, J.Y., Gordon, R., Gresser, M., Guay, J., Kargman, S., Kennedy, B., Leblanc, Y., Leger, S., Mancini, J., O’Neill, G.P., Oullet, M., Patrick, D., Percival, M.D., Perrier, H., Prasit, P., Rodger, I., Tagari, P., Therien, M., Vickers, P., Visco, D., Wang, Z., Webb, J., Wong, E., Xu, L.-J., Young, R.N., Zamboni, R. & Riendeau, D. (1999) Rofecoxib [Vioxx, MK-0966; 4-(4’-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Journal of Pharmacology and Experimental Therapeutics, 290, 551560.
  • Cheng, H.F. & Harris, R.C. (2004) Cyclooxygenases, the kidney, and hypertension. Hypertension, 43, 525530.
  • Chipkin, R.E., Latranyi, M.B., Iorio, L.C. & Barnett, A. (1983) Determination of analgesic drug efficacies by modification of the Randall and Selitto rat yeast paw test. Journal of Pharmacological Methods, 10, 223229.
  • Clarke, T.P. (2006) The clinical pharmacology of cyclooxygenase-2-selective and dual inhibitors. Veterinary Clinics of North America, 36, 10611085.
  • Cryer, B. & Feldman, M. (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. American Journal of Medicine, 104, 413421.
  • Dawson, J., Rordorf-Adam, C., Geiger, T., Towbin, H., Kunz, S., Nguyen, H., Zingel, O., Chaplin, D. & Vosbeck, K. (1993) Interleukin-1 (IL-1) production in a mouse tissue chamber model of inflammation. I. Development and initial characterisation of the model. Agents and Actions, 38, 247254.
  • Duncan, J.R., Prasse, J.R. & Mahaffey, E.A. (1995) Veterinary Laboratory Medicine: Clinical Pathology, 3rd edn. Iowa State University press, Ames IA.
  • Esser, R., Berry, C., Du, Z., Dawson, J., Fox, A., Fujimoto, R.A., Haston, W., Kimble, E.F., Koehler, J., Peppard, J., Quadros, E., Quintavalla, J., Toscano, K., Urban, L., Van Duzer, J., Zhang, X., Zhou, S. & Marshall, P.J. (2005a) Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2. British Journal of Pharmacology, 144, 538550.
  • Esser, R.E., Miserendino-Molteni, R., Sharr, M., Zhang, X., Porter, W., Ramos, L., Cramer, J.A., Zhuang, S., Georgieva, A. & Maniara, W. (2005b) Pharmacodynamic behaviour of the selective cyclooxygenase-2 inhibitor lumiracoxib in the lipopolysaccharide-stimulated rat air pouch model. European Journal of Pharmacological Sciences, 25, 2530.
  • Farkouh, M., Kirshner, H., Harrington, R., Ruland, S., Verheugt, F., Schnitzer, T., Burmester, G., Mysler, E., Hochberg, M., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Gimona, A., Matchaba, P., Hawkey, C. & Chesebro, J., on behalf of the TARGET Study Group. (2004) Therapeutic Arthritis Research and Gastrointestinal Event Trial: a randomised controlled trial of lumiracoxib vs naproxen and ibuprofen: cardiovascular outcomes. The Lancet, 364, 675684.
  • Flower, R.J. (2003) The development of COX2 inhibitors. Nature Reviews Drug Discovery, 2, 179191.
  • Futaki, N., Yoshikawa, K., Hamasaka, Y., Arai, I., Higuchi, S., Iizuka, H. & Otomo, S. (1993) NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions. General Pharmacology, 24, 105110.
  • Gierse, J.K., Koboldt, C.M., Walker, M.C., Seibert, K. & Isakson, P.C. (1999) Kinetic basis for selective inhibition of cyclo-oxygenases. Biochemical Journal, 339, 607614.
  • Gilroy, D.W., Tomlinson, A. & Willoughby, D.A. (1998) Differential effects of inhibitors of cyclooxygenase (cyclooxygenase 1 and cyclooxygenase 2) in acute inflammation. European Journal of Pharmacology, 355, 211217.
  • Gilroy, D.W., Colville-Nash, P.R., Willis, D., Chivers, J., Paul-Clark, M.J. & Willoughby, D.A. (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nature Medicine, 5, 598701.
  • Giraudel, J.M., Toutain, P.L. & Lees, P. (2005) Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and application for predicting the selectivity of NSAIDs in the cat. American Journal Veterinary Research, 66, 700709.
  • Hunt, R.H., Harper, S., Watson, D.J., Yu, C., Quan, H., Lee, M., Evans, J.K. & Oxenius, B. (2003) The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events. American Journal of Gastroenterology, 98, 17251733.
    Direct Link:
  • Jung, M., Lees, P., Seewald, W. & King, J.N. (2009) Analytical determination and pharmacokinetics of robenacoxib in the dog. Journal of Veterinary Pharmacology and Therapeutics, 32, 4148.
  • Kido, H., Murakami, N., Ito, A., Kimura, K., Kodera, N., Doi, T. & Naruse, T. (1998) Anti-inflammatory, analgesic and anti-pyretic effects of d-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid (M-5011), a new non-steroidal anti-inflammatory drug, in rats and guinea pigs. Japanese Journal of Pharmacology, 76, 7586.
  • Krausse, M.M., Brand, M.D., Krauss, S., Meisel, C., Vergin, H., Burmester, G.R. & Buttgereit, F. (2003) Nonsteroidal antiinflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells. Arthritis and Rheumatism, 48, 14381444.
  • Kujubu, D.A., Fletcher, B.S., Varnum, B.C., Lim, R.W. & Herschman, H.R. (1991) TIS10, a phorbol ester tumorpromoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. Journal of Biological Chemistry, 266, 1286612872.
  • Kulmacz, R.J. & Lands, W.E. (1985) Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents. Journal of Biological Chemistry, 260, 1257212578.
  • Lees, P., Creed, R.F.S., Gerring, E.L., Gould, P.W., Humphreys, D.J., Maitho, T.E., Michell, A.R. & Taylor, J.B. (1983) Biochemical and haematological effects of recommended dosage with phenylbutazone in horses. Equine Veterinary Journal, 15, 158167.
  • Lees, P., Landoni, M.F., Giraudel, J. & Toutain, P.L. (2004a) Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in species of veterinary interest. Journal of Veterinary Pharmacology and Therapeutics, 27, 479490.
  • Lees, P., Giraudel, J., Landoni, M.F. & Toutain, P.L. (2004b) PK-PD integration and PK-PD modeling of nonsteroidal anti-inflammatory drugs: principles and applications in veterinary pharmacology. Journal of Veterinary Pharmacology and Therapeutics, 27, 491502.
  • Li, J.J., Norton, M.B., Reinhard, E.J., Anderson, G.D., Gregory, S.A., Isakson, P.C., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Seibert, K., Zhang, Y., Zweifel, B.S. & Reitz, D.B. (1996) Novel terphenyls as selective cyclooxygenase-2 inhibitors and orally active anti-inflammatory agents. Journal of Medicinal Chemistry, 39, 18461856.
  • Lichtenberger, L.M., Dial, E.J., Romero, J.J., Lechago, J., Jarboe, L.A. & Wolfe, M.M. (1995) Role of luminal ammonia in the development of gastropathy and hypergastrinemia in the rat. Gastroenterology, 108, 320329.
  • Mamdani, M., Juurlink, D.N., Lee, D.S., Rochon, P.A., Kopp, A., Naglie, G., Austin, P.C., Laupacis, A. & Stukel, T.A. (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. The Lancet, 363, 17511756.
  • Mangold, J.B., Gu, H., Rodriguez, L.C., Bonner, J., Dickson, J. & Rordorf, C. (2004) Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects. Drug Metabolism and Disposition, 32, 566571.
  • Masferrer, J.L., Zweifel, B.S., Manning, P.T., Hauser, S.D., Leahy, K.M., Smith, W.G., Isakson, P.C. & Seibert, K. (1994) Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proceedings of the National Academy of Sciences of the United States of America, 91, 32283232.
  • McCann, M.E., Andersen, D.R., Zhang, D., Brideau, C., Black, W.C., Hanson, P.D. & Hickey, G.J. (2004) In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. American Journal of Veterinary Research, 65, 503512.
  • Moore, N. (2007) Diclofenac potassium 12.5 mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety. Clinical Drug Investigations, 27, 163195.
  • Mukherjee, A., Hale, V.G., Borga, O. & Stein, R. (1996) Predictability of the clinical potency of NSAIDs from the preclinical pharmacodynamics in rats. Inflammation Research, 45, 531540.
  • Nakano, M., Denda, N., Matsumoto, M., Kawamura, M., Kawakubo, Y., Hatanaka, K., Hiramoto, Y., Sato, Y., Noshiro, M. & Harada, Y. (2007) Interaction between cyclooxygenase (COX)-1- and COX-2 expression in the late phase of acute inflammation. European Journal of Pharmacology, 559, 210218.
  • Pairet, M. & Engelhardt, G. (1996) Distinct isoforms (COX-1 and COX-2) of cyclooxygenase: possible physiological and therapeutic implications. Fundamental Clinical Pharmacology, 10, 117.
  • Patrignani, P., Panara, M.R., Greco, A., Fusco, O., Natoll, C., Iacobelli, S., Cipollone, F., Ganci, A., Creminon, C. & Maclouf, J. (1994) Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. Journal of Pharmacology and Experimental Therapeutics, 271, 17051712.
  • Pinheiro, R.M. & Calixto, J.B. (2002) Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflammation Research, 51, 603610.
  • Pollmeier, M., Toulemonde, C., Fleishmann, C. & Hanson, P.D. (2006) Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Veterinary Record, 159, 547551.
  • Randall, L.O. & Selitto, J.J. (1957). A method for measurement of analgesic activity on inflamed tissue. Archives Internationale Pharmacodynamie, CXI, 409419.
  • Renton, K.W. (2001) Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacology & Therapeutics, 92, 147163.
  • Riendeau, D., Percival, M.D., Brideau, C., Charleson, S., Dube, D., Ethier, D., Falgueyret, J.P., Friesen, R.W., Gordon, R., Greig, G., Guay, J., Mancini, J., Ouellet, M., Wong, E., Xu, L., Boyce, S., Visco, D., Girard, Y., Prasit, P., Zamboni, R., Rodger, I.W., Gresser, M., Ford-Hutchinson, A.W., Young, R.N. & Chan, C.C. (2001) Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. Journal of Pharmacology and Experimental Therapeutics, 296, 558566.
  • Rordorf, C., Choi, L., Marshall, P. & Mungold, J.B.. (2005) Clinical pharmacology of lumiracoxib: a selective cyclo-oxygenase-2 inhibitor. Clinical Pharmacokinetics, 44, 12471266.
  • Schnitzer, T., Burmester, G., Mysler, E., Hochberg, M., Doherty, M., Ehrsam, E., Gitton, X., Krammer, G., Mellein, B., Matchaba, P., Gimona, A. & Hawkey, C., on behalf of the TARGET Study Group. (2004) Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) a randomised controlled trial of lumiracoxib vs naproxen and ibuprofen: reduction in ulcer complications. The Lancet, 364, 665674.
  • Scott, G., Rordorf, C., Blood, P., Branson, J., Milosavlijev, S. & Greig, G. (2002) Dose escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of COX189 in healthy subjects. Annals of Rheumatic Diseases, 61 (Suppl. 1), 242.
  • Scott, G., Rordorf, C., Reynolds, C., Kalbag, J., Looby, M., Milosavljev, S., Weaver, M., Huff, J.P. & Ruff, D.A. (2004) Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clinical Pharmacokinetics, 43, 467478.
  • Sedgwick, A.D. & Lees, P. (1986) Studies of eicosanoid production in the air pouch model of synovial inflammation. Agents and Actions, 18, 429438.
  • Sedgwick, A.D., Sin, Y.M., Edwards, J.C. & Willoughby, D.A. (1983) Increased inflammatory reactivity in newly formed lining tissue. Journal of Pathology, 141, 483495.
  • Simon, L.S., Lanza, F.L., Lipsky, P.E., Hubbard, R.C., Talwalker, S., Schwartz, B.D., Isakson, P.C. & Geis, G.S. (1998) Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheumatism, 41, 15911602.
  • Smale, S. & Bjarnason, I. (2003) Determining small bowel integrity following drug treatment. British Journal of Clinical Pharmacology, 56, 284291.
  • Smith, W.L. & Langenbach, R. (2001) Why there are two cyclooxygenase isozymes. Journal of Clinical Investigation, 107, 14911495.
  • Smith, J.B. & Willis, A.L. (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biology), 231, 235237.
  • Smith, W.L., Dewitt, D.L. & Garavito, R.M. (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annual Review of Biochemistry, 69, 145182.
  • Talley, J.J., Brown, D.L., Carter, J.S., Graneto, M.J., Koboldt, C.M., Masferrer, J.L., Perkins, W.E., Rogers, R.S., Shaffer, A.F., Zhang, Y.Y., Zweifel, B.S. & Seibert, K. (2000) 4-[5-Methyl-3-phenylisoxazol-4-yl]-benzene-sulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. Journal of Medicinal Chemistry, 43, 775777.
  • Taylor, J.B., Walland, A., Lees, P., Gerring, E.L., Maitho, T.E. & Millar, J.D. (1983) Biochemical and haematological effects of a revised dosage schedule of phenylbutazone in horses. Veterinary Record, 112, 599602.
  • Toutain, P.L. & Bousquet-Melou, A. (2004) Plasma clearance. Journal of Veterinary Pharmacology and Therapeutics, 27, 415425.
  • Vane, J.R. (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biology), 231, 232235.
  • Wagner, J.G. (1967) Method of estimating relative absorption of a drug in a series of clinical studies in which blood levels are measured after single and/or multiple doses. Journal of Pharmaceutical Sciences, 72, 838842.
  • Wallace, J.L., Chapman, K. & McKnight, W. (1999) Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. British Journal of Pharmacology, 126, 12001204.
  • Warner, T.D., Giuliano, F., Vojnovi, I., Bukasa, A., Mitchell, J.A. & Vane, J.R. (1999) Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proceedings of the National Academy of Sciences of the United States of America, 96, 75637568.
  • Wennogle, L.P., Liang, H., Quintavalla, J.C., Bowen, B.R., Wasvary, J., Miller, D.B., Allentoff, A., Boyer, W., Kelly, M. & Marshall, P. (1995) Comparison of recombinant cyclooxygenase-2 to native isoforms: aspirin labeling of the active site. FEBS Letters, 371, 315320.
  • Willoughby, D.A., Moore, A.R., Colville-Nash, D.R. & Gilroy, D. (2000) Resolution of inflammation. International Journal of Immunopharmacology, 22, 11311135.
  • Winter, C.A. & Flataker, L. (1965) Reaction thresholds to pressure in edematous hindpaws of rats and responses to analgesic drugs. Journal of Pharmacology and Experimental Therapeutics, 150, 165171.
  • Xie, W.L., Chipman, J.G., Robertson, D.S., Erikson, R.L. & Simmons, D.L. (1991) Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proceedings of the National Academy of Sciences of the United States of America, 88, 26922696.